Editas Medicine to Present at the 39th Annual J.P. Morgan Healthcare Conference
Editas Medicine (Nasdaq: EDIT) announced it will present an overview at the 39th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Editas Medicine (Nasdaq: EDIT) announced it will present an overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The event will be held virtually, and a live webcast will be accessible on Editas Medicine's website, with an archived replay available for 30 days post-presentation. As a leader in genome editing, Editas focuses on CRISPR technologies to develop precision genomic medicines for serious diseases globally.
Details
News Market Reaction – EDIT
The recorded move for EDIT in the trading session of this news was +7.33%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview at the 39th Annual J.P. Morgan Healthcare Conference, held virtually, on Wednesday, January 13, 2021, at 10:50 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available on the website for approximately 30 days following the presentation.
About Editas Medicine
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Contacts:
Investors
Editas Medicine Investor Relations
(617) 401-9052
ir@editasmed.com
Media
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.